Gemeinschaftspraxis Haematologie Onkologie — Clinical Trial Site

52 Registered trials

27 Currently recruiting

Organisation

Gemeinschaftspraxis Haematologie Onkologie

Location

Dresden, Germany

Identifier

ORG-100043081

Address

Arnoldstraße 18, Johannstadt-Nord, 01307, Germany

Departments

-
#2042:Hämatologie und Onkologie
#2100 Gemeinschaftspraxis Hämatologie-Onkologie
#2508: Gemeinschaftspraxis Haematologie und Onkologie
#3450: Private Practice
#5008:Jacobasch, Illmer, Wolf
049027:
2507
BAG Onkologische Gemeinschaftspraxis
DE10053:Jacobasch, Illmer, Wolf
Gemeinschaftspraxis
Gemeinschaftspraxis Freiberg-Richter, Jacobasch, Illmer, Wolf Haematologie, Onkologie
Gemeinschaftspraxis Hämatologie - Onkologie
Gemeinschaftspraxis Hämatologie – Onkologie, Freiberg-Richter, Jacobasch, Illmer, Wolf
Gemeinschaftspraxis Hämatologie- Onkologie, Dresden
Gemeinschaftspraxis Hämatologie-Omkologie
Gemeinschaftspraxis Hämatologie-Onkologie
Gemeinschaftspraxis Hämatologie-Onkologie Dresden
Haemato- Onkologie
Hämaologie-Onkologie
Hämatologie- Onkologie
Hämatologie/Onkologie
Hematology and Oncology
Innere Medizin/Hämatologie
Internal Medicine and Hematology and Oncology
n.a.
N/A
NA
not applicable
Oncology
Onkologie
Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf
Onkologische Gemeinschaftspraxis
Onkologische Gemeinschaftspraxis Dresden
Onkologische Schwerpunktpraxis

Clinical trials at this site (52)

Search interface

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Pending

2025-523521-18-00 Metastatic Colorectal Cancer 5
A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending

2025-523555-66-00 Myelofibrosis 5
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 HER2-positive breast cancer 4 2026-03-25
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting

2024-510635-21-00 warm autoimmune haemolytic anaemia (wAIHA) 5 2023-05-09
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-11-03
Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD-… Recruiting

2024-520264-33-00 Locoregionally recurrent head and neck squamous cell ca 5 2025-10-07
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Relapsed/Refractory Follicular Lymphoma 5 2025-09-03
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Multiple myeloma 5 2025-04-30
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 patients with hormone receptor (HR)-positive, HER2-nega 4 2024-12-10
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting

2022-502276-23-00 JAK2V617F-positive high-risk Polycythemia Vera 5 2024-04-25
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in … Recruiting

2022-501941-63-00 Multiple myeloma 7 2023-12-13
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24